2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002422 证券简称：科伦药业 公告编号：2025-069 四川科伦药业股份有限公司 特别提示： 1.本次股东大会未出现否决议案的情形； 2.本次股东大会未涉及变更前次股东大会决议事项。 一、会议召开情况 1.会议召开时间： 现场会议时间：2025年9月15日下午15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月15日上午9:15- 9:25、9:30-11:30，下午13:00-15:00期间任意时间；通过深圳证券交易所互联网投票系统投票的具体时 间为2025年9月15日9:15-15:00期间任意时间。 2.现场会议召开地点：公司会议室（成都市青羊区百花西路36号） 3.会议召开方式：现场表决与网络投票相结合 4.会议召集人：公司董事会 （1）现场会议出席情况 出席现场会议的股东及股东代理人共12名，代表股份423,348,083股，占公司有表决权股份总数的 26.612 ...

Group 1 - The company has successfully issued the second phase of its technology innovation bonds for the year 2025, with the funds fully received on September 12, 2025 [2][4] - The total amount registered for the short-term financing bonds is RMB 4 billion, valid for two years from the date of the acceptance notice [2] - The funds raised from the bond issuance will be used to repay existing debts and supplement working capital [2] Group 2 - The second temporary shareholders' meeting for the year 2025 was held on September 15, 2025, with a total of 317 shareholders and proxies present, representing 600,498,166 shares, which is 37.7486% of the total voting shares [7][8] - No resolutions were rejected during the shareholders' meeting, and there were no changes to previous resolutions [4][11] - Legal opinions were provided by Beijing Zhonglun (Chengdu) Law Firm, confirming the legality and validity of the meeting's procedures and resolutions [13]

Group 1 - The core point of the article is that Kelun Pharmaceutical announced the issuance of its second phase of technology innovation bonds for the year 2025, which took place on September 11, 2025, and the funds were fully received on September 12, 2025 [2] Group 2 - The company successfully raised funds through the bond issuance, indicating a positive step towards financing its technological innovations [2] - The announcement reflects the company's ongoing commitment to enhancing its research and development capabilities through financial instruments [2] - The timing of the bond issuance suggests strategic planning by the company to secure funding for future projects [2]

证券代码：002422 证券简称：科伦药业 公告编号：2025-069 四川科伦药业股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形； 2.本次股东大会未涉及变更前次股东大会决议事项。 一、会议召开情况 1.会议召开时间： 现场会议时间：2025年9月15日下午15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年9月15日上午9:15-9:25、9:30-11:30，下午13:00-15:00期间任意时间；通过 深圳证券交易所互联网投票系统投票的具体时间为2025年9月15日9:15-15:00期 间任意时间。 2.现场会议召开地点：公司会议室（成都市青羊区百花西路36号） 3.会议召开方式：现场表决与网络投票相结合 4.会议召集人：公司董事会 5.会议主持人：刘革新先生 本次股东大会的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定。 二、会议出席情况 1.出席公司本次会议的股东及股 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-068 四川科伦药业股份有限公司 2025年度第二期科技创新债券发行结果的公告 四川科伦药业股份有限公司董事会 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）《关于公司发行非金融 企业债务融资工具的议案》已于2023年4月12日经公司第七届董事会第二十六次 会议审议通过，并经2023年5月4日召开的公司2022年年度股东大会审议批准。 相关董事会和股东大会决议公告已分别于2023年4月14日和2023年5月5日披露 在《证券时报》《上海证券报》《证券日报》《中国证券报》以及公司指定信 息披露网站巨潮资讯网（www.cninfo.com.cn）。 公司于2023年12月25日收到中国银行间市场交易商协会（以下简称"交易 商协会"）于2023年12月21日下发的《接受注册通知书》（以下简称《通知书》） （中市协注[2023]SCP529号），交易商协会同意接受公司超短期融资券注册， 超短期融资券注册金额为人民币40亿元，注册额度自《通知书》落款之日起2 年内有 ...

法律意见书 北京中伦（成都）律师事务所 关于四川科伦药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：四川科伦药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会《上市 公司股东会规则》、《深圳证券交易所上市公司股东会网络投票实施细则》（以 下简称"《网络投票实施细则》"）等法律、法规及规范性文件的规定，北京中 伦（成都）律师事务所（以下简称"中伦"或"本所"）指派律师出席了四川科 伦药业股份有限公司（以下简称"公司"或"科伦药业"）2025 年第二次临时 股东大会（以下简称"本次股东大会"），并对本次股东大会的相关事项进行见 证。 本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以前已 经发生或者存在的事实，严格履行了法定职责，遵循勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、完整，所 发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并 承担相应法律 ...

Group 1 - The donation event at Han Ying Runze School in Baoshan, Yunnan, involved collaboration between Kanta Public Welfare and executives from listed companies in Yunnan, including Yangguang Lighting and Dinghan Technology [1][2] - Various companies contributed items such as backpacks, LED desk lamps, and a test paper scanner, along with over a thousand books and stationery from Sichuan companies [1] - The donations aim to improve the school's teaching conditions and meet the students' living needs, highlighting the role of corporate social responsibility in education [1][2] Group 2 - The visit allowed company executives to understand the school's unique educational features and daily life, establishing direct communication channels between listed companies and remote educational institutions [2] - This face-to-face interaction enhances the transparency and trust of the charitable projects, allowing donors to see the impact of their contributions [2] - Kanta Public Welfare, initiated by Kanta Consulting, serves as a platform for listed companies to effectively engage in social responsibility practices [2]

Core Viewpoint - Kolun Pharmaceutical is facing a significant decline in both revenue and net profit, with a 23.20% year-on-year decrease in revenue and a 44.41% drop in net profit, primarily due to falling demand in its core infusion and non-infusion segments, alongside high R&D costs [1][2][4] Revenue and Profit Performance - The company's revenue for the first half of the year was 9.083 billion yuan, marking a 23.20% decline and falling below the 10 billion yuan threshold for the first time [2] - The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2] - The infusion and non-infusion segments contributed nearly 90% of total revenue but both saw nearly a 20% decline [2] Business Structure and Challenges - Analysts indicate that the company's heavy reliance on a concentrated business structure has created vulnerabilities, leading to significant performance drops when core business areas face challenges [4] - The infusion segment's gross margin decreased by 6.19 percentage points compared to the previous year, reflecting the dual impact of reduced volume and price [4][6] Cash Flow and Financing - The net cash flow from operating activities was 1.190 billion yuan, a 53.03% decrease from the previous year, primarily due to reduced sales collections [5] - Financing activities shifted from a net outflow of 883 million yuan to a net inflow of 1.168 billion yuan, aided by a capital increase from a subsidiary [5] Market Conditions and Future Outlook - The basic infusion market is expected to hit a bottom by 2025, but the timing of a rebound remains uncertain [6] - The company is focusing on high-end infusion products as a long-term strategy, with several new products approved for market [7] - The competitive landscape is shifting towards product quality and service levels rather than price, which may stabilize the market [9] Antibiotic Market Dynamics - The core subsidiary, Chuaning Biological, reported a revenue decline of 26.5% year-on-year, largely due to weakening market conditions for penicillin [10] - The penicillin market is currently at a low point, with expectations of a significant decline in annual performance for Chuaning Biological [10][12] - The company is exploring new markets, including veterinary antibiotics, to mitigate the cyclical downturn in its antibiotic business [13]

Investment Rating - The report maintains an "Overweight" rating for the innovative drug sector, indicating that the industry is expected to outperform the overall market [5][11]. Core Insights - The report emphasizes the long-term investment value of Chinese innovative drugs, highlighting three main supporting logics: innovation upgrades, profitability inflection points, and normalization of outbound business development (BD) [5]. - Chinese biotech companies are demonstrating significant capabilities in global innovation, with notable products emerging in the PD-1/VEGF dual antibody and EGFR/c-MET dual antibody ADC categories [5]. - Leading biotech firms like BeiGene and Innovent Biologics are projected to reach profitability in 2025, suggesting a sustained high growth trajectory for the sector [5]. - The total value of license-out agreements from mainland China to Europe and the US has reached $94.3 billion as of September 2025, significantly surpassing the $51.9 billion recorded for the entirety of 2024 [5]. Summary by Sections Industry Overview - The report discusses the potential impact of a proposed US government draft that aims to limit American pharmaceutical companies from acquiring experimental drugs from China, although the likelihood of this draft being implemented is considered low [5]. - The report argues that even if the US tightens regulations, Chinese biotech can still pursue collaborations with European firms and establish overseas companies to navigate these restrictions [5]. Company Valuations - The report includes a valuation table for key companies in the pharmaceutical and biotech sector, detailing market capitalization, earnings per share (EPS) projections, and price-to-earnings (PE) ratios for 2024 to 2027 [6]. - Notable companies mentioned include: - Hengrui Medicine with a market cap of 453.3 billion yuan and a projected PE ratio of 68.3 for 2024 [6]. - BeiGene with a market cap of 436.5 billion yuan, expected to turn profitable by 2026 [6]. - Innovent Biologics and other firms are also highlighted for their growth potential and market performance [6].

证券代码：002422 证券简称：科伦药业 公告编号：2025-067 四川科伦药业股份有限公司 关于签订募集资金监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准四川科伦药业股份有限公司公开发行 可转换公司债券的批复》（证监许可[2022]255 号）核准，四川科伦药业股份有 限公司（以下简称"公司"）于 2022 年 3 月 18 日公开发行 3,000.00 万张可转换 公司债券，发行价格为每张 100 元，募集资金总额为人民币 300,000.00 万元，扣 除承销保荐费及其他发行费用人民币 1,994.60 万元（不含税）后，募集资金净额 为人民币 298,005.40 万元。以上募集资金到位情况已经毕马威华振会计师事务所 （特殊普通合伙）进行验资，并出具了"毕马威华振验字第 2200707 号"《募集 资金验证报告》。 二、本次募集资金专户的开立及监管协议的签订情况 公司于 2025 年 8 月 27 日分别召开了第八届董事会第八次会议、第八届监事 会第七次会议，审议通过了《关于 ...